Committed to using chemical concepts to solve problems in the fields of new materials and medicine
MORE +
Starting from the end, deeply understanding customers, products, and quality, empowering the pharmaceutical industry with chemistry
MORE +
Become the industry leader in the segmented field of fine chemical product manufacturers
MORE +About Ruichen Kangda Biopharmaceutical (Wuhan) Co., Ltd.
Ruichen Kangda Biopharmaceutical (Wuhan) Co., Ltd. was registered and established in August 2018 in Donghu High tech Development Zone, Wuhan. The company has a strong R&D team led by several senior overseas returnees and PhDs. The core team mostly has many years of work experience in large pharmaceutical R&D enterprises and has mature drug development and marketing capabilities.
The company focuses on the synthesis of innovative drug intermediates, process development and synthesis of high-end generic drug raw materials, and synthesis of functional new materials. Adhering to the core concept based on synthetic chemistry, we are committed to developing new processes and methods, building products in a green and efficient manner, and solving the problems of product accessibility from 0 to 1 and efficient product acquisition from 1 to 100. At present, the company relies on its strong chemical synthesis capabilities and conducts research and development of new processes and methods to achieve efficient synthesis of differentiated products at a greener and lower cost, breaking the existing technological monopoly and better meeting market demand. Therefore, the large-scale production of multiple products has been successfully completed. In addition, based on common technologies, the company has successfully developed multiple independently initiated projects such as polysaccharide drugs, metal sugar complexes, and solubilization degradable materials, with extremely broad market prospects.
Ruichen Kangda Biopharmaceutical (Wuhan) Co., Ltd. will continuously explore and advance in the field of biomedicine with its strong research and innovation capabilities, contribute to the development of the industry, and create more value for human health.
Corporate Promotional Film
VIDEO DISPLAY
-
2018
Establishment time
-
5
+Product series 5+
-
100
+Collaborative projects 100+
-
1000
+Partners 1000+
-
99
%+Customer satisfaction 99%+
Products
Service Support
Through continuous learning and efforts, we improve our R & D capabilities and efficiency to provide customers with more efficient and faster chemical services. We provide customers with R & D and production of APIs and intermediates from gram to kilogram, realizing seamless one-stop service, reducing additional costs and greatly shortening the R & D cycle. We provide efficient technical services and solutions to help and accelerate the drug development process and reduce the cost of research and development.
Learn more
SERVICE
News Center
On May 19, 2022, braving the wind and drizzling rain, in Jingzhou, a beautiful ancient city from east to west, south to north, Dr. Yang Yang, chief scientist and chairman of our company, and Mr. Liu Jun, general manager of our company, participated in the signing ceremony of the second quarter of Jingzhou Investment Promotion sponsored by the Communist Party of China Jingzhou Municipal Committee and Jingzhou Municipal People's Government, and hosted by Jingzhou Investment Promotion Center. The signing ceremony was held at Wanda Realm Jingzhou.
2022
05-20
On April 30, 2022, Songzi City People's Government Mayor Wang Wei, Deputy Mayor Li Wei, Secretary of China Merchants Bureau Qin Zhangyan, Director of the city Office in Han Xu Tao, Secretary of the Town Committee of Eight Bao Town Zou Feng and others visited Ruichen Kangda Bio-Medicine (Wuhan) Co., LTD. (hereinafter referred to as Ruichen Kangda) Optics Valley Bio-City R&D Center to investigate and guide the work. Mayor Wang Wei and his delegation visited the R & D center of Ruichen Kangda, and asked in detail the precautions in the test process and the use of various instruments and methods.
2022
05-20
With the continuous promotion of the "Healthy China 2030" strategy, the multi-level security model is becoming a new trend, and how to linkage all walks of life to help together has become the focus of attention of the industry. On September 21, Shanghai Pharmaceutical Holdings, Zhongre Life Insurance, Magnesin Health, and BCG jointly held the "Building a multi-level Medical Security System Summit Forum - and 2020 China Oncology Special Drug Payment Report Conference", and discussed the challenges and opportunities of a multi-level medical security system with 200 industry elites.
2020
10-15
Vitamin D helps cancer patients live longer, study finds
Doctors at Michigan State University have found that vitamin D can help cancer patients live longer if taken for at least three years.
2020
10-15
Beijing, September 30 On September 27, the fifth China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as "Venture Capital Conference") was held in Suzhou Industrial Park. This conference is co-sponsored by China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China Pharmaceutical Promotion Association"), China Medical Device Industry Association, Hong Kong Stock Exchange and Imelda Medical Consulting. The conference attracted nearly 2,000 representatives from more than 100 domestic and foreign investment institutions, pharmaceutical innovative enterprises and research institutes.
2020
10-15
Recruiting talents and talents
We have a high-quality and high-level research and development team led by a number of senior returnees.
Through continuous learning and efforts, we improve our R & D capabilities and efficiency to provide customers with more efficient and faster chemical services.
SAF Coolest v1.3 设置面板 GAGSD-ZGYF-JSZDE-ZXQ
无数据提示
Sorry, the current column has no content for the time being.!
You can view other columns or returnHome Page